Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02440685 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02440685 is a Phase 1 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 51 participants.
The verdict
NCT02440685, a Phase 1 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
Interventions
- DRUG ASN002 Dose Escalation
- DRUG ASN002 RD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02440685
The ClinicalTrials.gov registry entry for NCT02440685 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASN002 Dose Escalation is the first listed.
NCT02440685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02440685 about?
NCT02440685 is a clinical study titled "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors". This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
What is the current status of trial NCT02440685?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-05. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02440685?
The interventions under investigation include: ASN002 Dose Escalation (DRUG), ASN002 RD (DRUG).
Who is sponsoring clinical trial NCT02440685?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.